Studies | EBMT

Top

Study type

Disease

Group

Type of transplant / Cell therapy

Text

Language

Survey on fertility procedures and outcomes for patients treated with CAR-T cell therapy

Closed Survey/Study

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type de traitement

Investigateur principal

Giorgio Orofino

CAR-T in elderly patients

Études rétrospectives

Lymphome non hodgkinien (LNH)

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type de traitement

Investigateur principal

Vanderson Rocha

Disease-specificity effects of HLA mismatching effects in unrelated HCT under with PTCy-based GvHD prophylaxis

Études rétrospectives

Leucémie Aiguë Lymphoblastique (LAL)

Leucémie Myéloïde Aiguë (LMA)

Chronic Lymphocytic Leukaemia (CLL)

Leucémie Myéloïde Chronique (LMC)

Chronic Lymphocytic Leukaemia (CLL)

Syndrome Myélodysplasique (MDS) ou MDS/MPN

Autres tumeurs malignes myéloïdes ou lymphoïdes

Myélome multiple (MM) ou autre dyscrasies plasmocytaires (PCD)

Lymphome non hodgkinien (LNH)

Cellular Therapy & Immunobiology Working Party (CTIWP)

Acute Leukemia Working Party (ALWP)

Type de traitement

Allogénique - Non apparentée

Investigateur principal

HLA Mismatch Frequencies in Unrelated Hematopoietic Cell Transplantation

Retrospective Studies

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type de traitement

Allogeneic - Unrelated

Investigateur principal

Esteban Arrieta Bolaños

Impact of fludarabine dose modification in conditioning regimen for CAR T-cell therapy

Études rétrospectives

Lymphome non hodgkinien (LNH)

Leucémie Aiguë Lymphoblastique (LAL)

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type de traitement

Investigateur principal

Guillaume Dachy

Survey on the organization and techniques of ATMP facilities by DARE-NL, EBMT, T2Evolve, and NXTGEN-HIGHTECH - a GoCART-coalition initiative

Toutes les maladies

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type de traitement

Thérapie génique

Thérapies cellulaires (autres que DLI)

Investigateur principal

Infections following CAR-T therapy. A retrospective collaborative study between the Infectious Diseases Working Party (IDWP), the Cellular Therapy and Immunobiology Working Party (CTIWP), the Transplant Complications Working Party (TCWP) of the EBMT, the European Hematology Association (EHA), and the Medical College of Wisconsin.

Lymphome non hodgkinien (LNH)

Leucémie Aiguë Lymphoblastique (LAL)

GoCART Coalition

Infectious Diseases Working Party (IDWP)

Cellular Therapy & Immunobiology Working Party (CTIWP)

Transplant Complications Working Party (TCWP)

Type de traitement

Investigateur principal

Autoimmune and autoinflammatory complications after CAR-T cell therapy - a joint study on behalf of the EBMT - ADWP, CTIWP and TCWP

Études rétrospectives

Leucémie Aiguë Lymphoblastique (LAL)

Myélome multiple (MM) ou autre dyscrasies plasmocytaires (PCD)

Lymphome non hodgkinien (LNH)

GoCART Coalition

Autoimmune Diseases Working Party (ADWP)

Cellular Therapy & Immunobiology Working Party (CTIWP)

Transplant Complications Working Party (TCWP)

Type de traitement

Investigateur principal

Survey on the use of DLI after allogeneic after allogeneic stem cell transplantation across EBMT centers

Toutes les maladies

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type de traitement

Injection de lymphocyte de donneur (DLI)

Investigateur principal

Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone: A Retrospective Study on Behalf of the CTIWP

Études rétrospectives

Leucémie Aiguë Lymphoblastique (LAL)

Leucémie Myéloïde Aiguë (LMA)

Chronic Lymphocytic Leukaemia (CLL)

Leucémie Lymphoïde Chronique (LLC)

Chronic Lymphocytic Leukaemia (CLL)

Syndrome Myélodysplasique (MDS) ou MDS/MPN

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type de traitement

Allogénique - Haplo-identique

Investigateur principal

Potential factors influencing CAR-T cell manufacturing in terms of production failures and out of specification (OOS) products on behalf of EBMT - CTIWP

Toutes les maladies

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type de traitement

Investigateur principal

Defining protective immune cell subsets and subpopulations thresholds following allogeneic hematopoietic stem cell transplantation

Études rétrospectives

Toutes les maladies

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type de traitement

Investigateur principal

Marina Cavazzana